{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T18:10:22Z","timestamp":1783793422631,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.humpath.2026.106207","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:28:57Z","timestamp":1782257337000},"page":"106207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chronic myelomonocytic leukemia revisited: A comprehensive review with emphasis on the oligomonocytic subtype"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Montalban-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2026.106207_bib1","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ajh.27271","article-title":"Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management","volume":"99","author":"Patnaik","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.humpath.2026.106207_bib2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2026.106207_bib3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106207_bib4","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/modpathol.2017.45","article-title":"Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia","volume":"30","author":"Geyer","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2026.106207_bib5","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood.2025030689","article-title":"Advancing the classification of hematolymphoid neoplasms together: for patients, medicine, and science","volume":"147","author":"Hasserjian","year":"2026","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.humpath.2026.106207_bib6","article-title":"Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group","volume":"33","author":"JM","year":"1976","journal-title":"Br J Haematol"},{"key":"10.1016\/j.humpath.2026.106207_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2017.12.002","article-title":"Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML","volume":"65","author":"Schuler","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.humpath.2026.106207_bib8","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3324\/haematol.2019.222059","article-title":"Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions","volume":"104","author":"Valent","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2026.106207_bib9","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106207_bib10","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/blood-2024-205451","article-title":"CMML is in the eye of the be_who_ lder: interrogating the newly proposed entity of oligomonocytic chronic myelomonocytic leukemia (O-CMML): MDS or CMML?","volume":"144","author":"Komrokji","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106207_bib11","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1182\/blood.2023021199","article-title":"Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022","volume":"143","author":"Baumgartner","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106207_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100823","article-title":"Myeloid neoplasms with oligomonocytosis exhibit heterogenous pathologic and genetic features","volume":"38","author":"Baloda","year":"2025","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2026.106207_bib13","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/bjh.19217","article-title":"Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic","volume":"204","author":"Casta\u00f1o-D\u00edez","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.humpath.2026.106207_bib14","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1182\/bloodadvances.2022007359","article-title":"Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum","volume":"6","author":"Calvo","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2026.106207_bib15","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1182\/bloodadvances.2020002206","article-title":"Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features","volume":"4","author":"Calvo","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2026.106207_bib16","first-page":"OF1","article-title":"Multi-modal and data-driven assessment of myeloid neoplasms refines classification across disease states","author":"Lachowiez","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.humpath.2026.106207_bib17","doi-asserted-by":"crossref","DOI":"10.1158\/2643-3230.BCD-25-0264","article-title":"Incorporation of genomic determinants improves diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia","author":"Montalban-Bravo","year":"2026","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.humpath.2026.106207_bib18","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3324\/haematol.2008.005421","article-title":"Morphological evaluation of monocytes and their precursors","volume":"94","author":"Goasguen","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2026.106207_bib19","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1182\/blood-2015-01-620781","article-title":"Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia","volume":"125","author":"Selimoglu-Buet","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106207_bib20","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1182\/blood-2017-04-779579","article-title":"Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML","volume":"130","author":"Selimoglu-Buet","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106207_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-026-02901-w","article-title":"Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?","author":"Selimoglu-Buet","year":"2026","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2026.106207_bib22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/cyto.b.22176","article-title":"Technical, gating and interpretation recommendations for the partitioning of circulating monocyte subsets assessed by flow cytometry","volume":"106","author":"Tarfi","year":"2024","journal-title":"Cytom Part B-Clin Cy"},{"key":"10.1016\/j.humpath.2026.106207_bib23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/cyto.b.22106","article-title":"Optimization of monocyte gating to quantify monocyte subsets for the diagnosis of chronic myelomonocytic leukemia","volume":"104","author":"Jurado","year":"2023","journal-title":"Cytom Part B-Clin Cy"},{"key":"10.1016\/j.humpath.2026.106207_bib24","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/bloodadvances.2018024216","article-title":"Invariant phenotype and molecular association of biallelic mutant myeloid neoplasia","volume":"3","author":"Awada","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2026.106207_bib25","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1038\/s41375-022-01733-8","article-title":"Multi-hit TET2 mutations as a differential molecular signature of oligomonocytic and overt chronic myelomonocytic leukemia","volume":"36","author":"Garcia-Gisbert","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2026.106207_bib26","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/s41375-019-0690-7","article-title":"Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients","volume":"34","author":"Coltro","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2026.106207_bib27","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1080\/10428194.2024.2378816","article-title":"Predicting which subsets of patients with myelodysplastic neoplasms are more likely to progress to overt chronic myelomonocytic leukemia","volume":"65","author":"Tran","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.humpath.2026.106207_bib28","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-02116","article-title":"Molecular-based ecosystem to improve personalized medicine in chronic myelomonocytic leukemia","author":"Lanino","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2026.106207_bib29","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood.2023023727","article-title":"Molecular taxonomy of myelodysplastic syndromes and its clinical implications","volume":"144","author":"Bernard","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106207_bib30","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/s41375-023-01964-3","article-title":"Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)","volume":"37","author":"Gurney","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2026.106207_bib31","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1182\/bloodadvances.2024012565","article-title":"Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm","volume":"8","author":"Bataller","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2026.106207_bib32","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1182\/blood-2024-209126","article-title":"Comparative analysis of oligomonocytic CMML with myelodysplastic and myeloproliferative CMML subtypes: a study of 849 molecularly-annotated patients","volume":"144","author":"Csizmar","year":"2024","journal-title":"Blood"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817726001760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817726001760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T03:40:34Z","timestamp":1782531634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817726001760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":32,"alternative-id":["S0046817726001760"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2026.106207","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic myelomonocytic leukemia revisited: A comprehensive review with emphasis on the oligomonocytic subtype","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2026.106207","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106207"}}